NCT02243280View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Chronic Hepatitis CHepatitis C VirusHCV
Interventions
DRUG

ABT-493

Tablet

DRUG

ABT-530

Tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY

NCT02243280 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection | Biotech Hunter | Biotech Hunter